Aethlon Medical (NASDAQ:AEMD) Releases Earnings Results, Beats Expectations By $0.10 EPS

Aethlon Medical (NASDAQ:AEMD) released its quarterly earnings results on Wednesday. The medical equipment provider reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.10, Yahoo Finance reports. During the same quarter in the prior year, the business earned ($1.30) EPS.

Aethlon Medical Price Performance

NASDAQ AEMD traded down $0.06 on Thursday, reaching $0.32. The company had a trading volume of 930,623 shares, compared to its average volume of 1,973,093. The firm has a market cap of $4.45 million, a price-to-earnings ratio of -0.07 and a beta of 1.65. Aethlon Medical has a fifty-two week low of $0.24 and a fifty-two week high of $3.30. The business has a 50 day moving average of $0.45 and a two-hundred day moving average of $1.07.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. StockNews.com assumed coverage on shares of Aethlon Medical in a research report on Sunday, June 23rd. They issued a “sell” rating for the company. HC Wainwright lowered their price objective on shares of Aethlon Medical from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, June 24th.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.